CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Rituximab-Dependent Cytotoxicity by Natural Killer Cells

Dall’Ozzo, Sébastien, Tartas, Sophie, Paintaud, Gilles, Cartron, Guillaume, Colombat, Philippe, Bardos, Pierre, Watier, Hervé, Thibault, Gilles · 2004 · Cancer Research

Abstract

The FCGR3A gene dimorphism generates two allotypes: FcgammaRIIIa-158V and FcgammaRIIIa-158F. The genotype homozygous for FcgammaRIIIa-158V (VV) is associated with higher clinical response to rituximab, a chimeric anti-CD20 IgG1 used in the treatment of B lymphoproliferative malignancies. Our objective was to determine whether this genetic association relates to rituximab-dependent cytotoxicity mediated by FcgammaRIIIa/CD16a+ cells. The number of CD16+ circulating monocytes, T cells, and natural killer (NK) cells in 54 donors was first shown to be unrelated to FCGR3A polymorphism. We then demonstrated that FcgammaRIIIa-158V displays higher affinity for rituximab than FcgammaRIIIa-158F by comparing rituximab concentrations inhibiting the binding of 3G8 mAb (anti-CD16) with VV NK cells and NK cells homozygous for FcgammaRIIIa-158F (FF). VV and FF NK cells killed Daudi cells similarly after FcgammaRIIIa engagement by saturating concentrations of rituximab or 3G8. However, the rituximab concentration resulting in 50% lysis (EC(50)) observed with NK cells from VV donors was 4.2 times lower than that observed with NK cells from FF donors (on average 0.00096 and 0.00402 microg/ml, respectively, P = 0.0043). Finally, the functional difference between VV and FF NK cells was restricted to rituximab concentrations weakly sensitizing CD20. This study supports the conclusion that FCGR3A genotype is associated with response to rituximab because it affects the relationship between rituximab concentration and NK cell-mediated lysis of CD20+ cells. Rituximab administration could therefore be adjusted according to FCGR3A genotype.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-03-2862

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

See all 456

Metadata

Authors
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G.
Affiliations
  • 1Laboratoire d’Immunologie,
  • Université de Tours (FR)
Venue
Cancer Research
Published
2004-07-01
Volume
64
Issue
13
Pages
4664-4669
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1914229355
Cited by
434
References
47
Citations by year
2026: 4 · 2025: 9 · 2024: 13 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 13 · 2019: 20 · 2018: 20 · 2017: 21 · 2016: 24 · 2015: 28 · 2014: 28 · 2013: 27 · 2012: 29
FWCI
6.99
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
rituximab, natural killer cells, FCGR2A, CD16, CD20, Daudi cells, individualized dosing
MeSH terms
Rituximab, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Cells, Cultured, Dose-Response Relationship, Immunologic, Genotype, Humans, Killer Cells, Natural, Polymorphism, Genetic, Receptors, IgG, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab-Dependent Cytotoxicity by Natural Killer Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-2862
The paper
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004). Rituximab-Dependent Cytotoxicity by Natural Killer Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-2862

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.